Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enanta Pharmaceuticals (NAS:ENTA) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Enanta Pharmaceuticals Earnings per Share (Diluted) Related Terms
Enanta Pharmaceuticals Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Enanta Pharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enanta Pharmaceuticals Earnings per Share (Diluted) Chart
ENTA vs LXEO, XFOR, GALT: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Enanta Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enanta Pharmaceuticals PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Enanta Pharmaceuticals's PE Ratio falls into.
Enanta Pharmaceuticals Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Enanta Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Sep. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-2.41 mean?
Enanta Pharmaceuticals (ENTA) has a Earnings per Share (Diluted) of $-2.41 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Enanta Pharmaceuticals and its competitors. According to the industry distribution chart, Enanta Pharmaceuticals ranks #627 out of 1160 companies in the Biotechnology industry, placing it in the top 54.1%.
Is Enanta Pharmaceuticals' Earnings per Share (Diluted) too high?
Enanta Pharmaceuticals' current Earnings per Share (Diluted) is $-2.41. Based on the distribution chart, Enanta Pharmaceuticals ranks #627 out of 1160 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Enanta Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Earnings per Share (Diluted) compare to LXEO and XFOR?
According to the Biotechnology industry distribution chart, Enanta Pharmaceuticals ranks #627 out of 1160 companies for Earnings per Share (Diluted). This places Enanta Pharmaceuticals in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Enanta Pharmaceuticals and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enanta Pharmaceuticals's current Earnings per Share (Diluted) is $-2.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (ENTA) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.89, compared to a current price of $13.31 — trading 68.6% above its estimated fair value. The current Earnings per Share (Diluted) is $-2.41. Enanta Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Enanta Pharmaceuticals (ENTA), the current Earnings per Share (Diluted) is $-2.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enanta Pharmaceuticals (ENTA) Overvalued in 2026?
Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued.
The current stock price of $13.31 is trading 68.6% above its estimated GF Value™ of $7.89.
GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ENTA:
Earnings per Share (Diluted): $-2.41
GF Value™: $7.89 vs. price of $13.31 (68.6% above fair value)
No single metric tells the full story. See the ENTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
56GF Score
Get the complete analysis for ENTA
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTA has been successfully added to your 
